Muscle Relaxant Drug Market To Reach $7.64 Billion by 2035

Muscle relaxant drug market was valued at $4.80 billion in 2025 and is projected to reach $7.64 billion by 2035, growing at a CAGR of 4.76% during the forecast period (2026–2035). The increasing prevalence of musculoskeletal disorders and neurological conditions is significantly driving demand for muscle relaxant drugs across global healthcare systems. Muscle relaxants are widely used for managing conditions such as lower back pain, muscle spasms, and spasticity associated with neurological disorders, supporting their widespread adoption across hospitals and specialty care settings. The market is witnessing steady demand growth due to rising chronic pain cases and increasing surgical procedures globally, where neuromuscular blocking agents are extensively used.

Browse the full report description of “Muscle Relaxant Drug Market Size, Share & Trends Analysis Report, By Drug Type (Centrally Acting Muscle Relaxants, Peripherally Acting Muscle Relaxants), By Indication (Musculoskeletal Disorders, Neurological Disorders, Surgical & Critical Care Use), By End-User (Hospitals, Specialty Clinics, Homecare Settings), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/muscle-relaxant-drug-market

Rising Burden of Musculoskeletal Disorders Driving Market Growth
According to the World Health Organization, musculoskeletal conditions affect approximately 1.71 billion people worldwide, making them the leading contributor to disability globally. This rising disease burden is increasing the need for pharmacological treatment options, including centrally acting and peripherally acting muscle relaxants. Additionally, the increasing geriatric population is contributing to higher incidence of muscle stiffness and chronic pain conditions, further supporting the adoption of muscle relaxant drugs across healthcare facilities.

Increasing Surgical Procedures and Hospital Demand Supporting Market Expansion
The growing number of surgical procedures worldwide is significantly contributing to the demand for muscle relaxant drugs, particularly in anaesthesia and critical care applications. According to the Organisation for Economic Co-operation and Development, the volume of surgical procedures across member countries has been steadily increasing, reflecting improved healthcare access and infrastructure. This trend is driving the use of injectable muscle relaxants in hospitals, which remain the dominant end-user segment. Additionally, specialty clinics and homecare settings are witnessing growing adoption due to the increasing preference for outpatient treatments and chronic disease management.

Key Leaders Transforming the Muscle Relaxant Drug Market

The key players in the muscle relaxant drug market include Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Ipsen Biopharmaceuticals Inc., and Novartis AG, among others. These companies are focusing on expanding their central nervous system drug portfolios, improving generic drug availability, and strengthening their global distribution networks to enhance market reach and accessibility.

• In December 2025, Nexus Pharmaceuticals announced the launch of Tacrolimus Injection, USP 5 mg/mL in a single-dose vial format, indicated for the prevention of organ rejection in liver and kidney transplant patients. The launch enhances accessibility to cost-effective immunosuppressant therapies and strengthens the company’s portfolio in complex injectable drugs.
• In November 2025, Novartis AG received approval from the U.S. Food and Drug Administration for Itvisma® (onasemnogene abeparvovec-brve), a one-time gene replacement therapy for patients aged two years and older with spinal muscular atrophy (SMA). The therapy targets the SMN1 gene to improve motor function and reduce dependence on chronic treatments, marking a significant advancement in genetic and neurological disorder therapeutics.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Drug Type
• Indication
• End-User
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape – Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Ipsen Biopharmaceuticals Inc., Novartis AG, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Muscle Relaxant Drug Market Report Segment

By Drug Type

• Centrally Acting Muscle Relaxants
• Peripherally Acting Muscle Relaxants

By Indication

• Musculoskeletal Disorders
• Neurological Disorders
• Surgical & Critical Care Use

By End-User

• Hospitals
• Specialty Clinics
• Homecare Settings

Global Muscle Relaxant Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/muscle-relaxant-drug-market